	US 12,295,983 B2
	Use of extracts of the leaves of lemon verbena (Aloysia citriodora) for increasing the neuronal, cerebral availability of neurotransmitters selected from the group of serotonin, dopamine, noradrenaline
Björn Feistel, Andernach (DE); Bernd Walbroel, Königswinter (DE); Bernd L. Fiebich, Freiburg (DE); and Kurt Appel, Bramsche (DE)
Assigned to Finzelberg GMBH & Co. KG, Adernach (DE)
Appl. No. 17/293,518
Filed by Finzelberg GMBH & Co. KG, Andernach (DE)
PCT Filed Nov. 14, 2019, PCT No. PCT/EP2019/081392 § 371(c)(1), (2) Date May 13, 2021, PCT Pub. No. WO2020/099595, PCT Pub. Date May 22, 2020.
Claims priority of application No. 18206340 (EP), filed on Nov. 14, 2018.
Prior Publication US 2022/0031794 A1, Feb. 3, 2022
Int. Cl. A61K 36/85 (2006.01); A61P 25/00 (2006.01)

CPC A61K 36/85 (2013.01) [A61P 25/00 (2018.01); A61K 2236/30 (2013.01)]

16 Claims

1. A method of treating a neurological disorder, the method comprising:

providing a formulation to a person to treat a neurological disorder,

wherein the neurological disorder is attention deficit hyperactivity disorder (ADHD), wherein the formulation comprises an extract prepared by alcoholic-aqueous extraction from leaves of lemon verbena (Aloysia citriodora) using an extractant having an alcohol concentration of 10-60% v/v and removal of volatiles by evaporation, wherein said extract has a content of essential oil of less than 0.05% by weight, based on the extract without additives.